Evidence map›Paper›PMID 39356625›Full record

ReviewCancer research2024

Resistance Management for Cancer: Lessons from Farmers.

Sareh Seyedi, Valerie K Harris, Stefania E Kapsetaki, Shrinath Narayanan, Daniel Saha, Zachary Compton, Rezvan Yousefi, Alexander May, Efe Fakir, Amy M Boddy and 8 more

Abstract readReview
In one paragraph

Review in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sareh SeyediArizona Cancer Evolution Center, Arizona State University, Tempe, Arizona.ORCID 0009-0006-3263-2055
Valerie K HarrisArizona Cancer Evolution Center, Arizona State University, Tempe, Arizona.ORCID 0000-0002-8577-4157
Stefania E KapsetakiArizona Cancer Evolution Center, Arizona State University, Tempe, Arizona.ORCID 0000-0002-9999-8573
Shrinath NarayananCenter for Biocomputing, Security and Society, Biodesign Institute, Arizona State University, Tempe, Arizona.ORCID 0000-0001-7205-4460
Daniel SahaArizona Cancer Evolution Center, Arizona State University, Tempe, Arizona.ORCID 0000-0001-5103-2465
Zachary ComptonArizona Cancer Evolution Center, Arizona State University, Tempe, Arizona.ORCID 0000-0002-0558-2316
Rezvan YousefiArizona Cancer Evolution Center, Arizona State University, Tempe, Arizona.ORCID 0009-0000-3706-0494
Alexander MayResearch Casting International, Quinte West, Ontario, Canada.ORCID 0000-0003-4521-6916
Efe FakirIstanbul University Cerrahpasa School of Medicine, Istanbul, Turkey.ORCID 0009-0006-6375-0994
Amy M BoddyArizona Cancer Evolution Center, Arizona State University, Tempe, Arizona.ORCID 0000-0002-7990-2415
Marco GerlingerTranslational Oncogenomics Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-2719-299X
Christina WuDivision of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0001-5922-5392
Lida MinaMayo Clinic, Phoenix, Arizona.ORCID 0000-0003-2606-9922
Silvie HuijbenSchool of Life Sciences, Arizona State University, Tempe, Arizona.ORCID 0000-0002-3537-1915
Dawn H GougeDepartment of Entomology, University of Arizona, Tucson, Arizona.ORCID 0000-0001-7725-2642
Luis CisnerosArizona Cancer Evolution Center, Arizona State University, Tempe, Arizona.ORCID 0000-0002-7890-1269
Peter C EllsworthDepartment of Entomology, University of Arizona, Tucson, Arizona.ORCID 0000-0002-2485-0830
Carlo C MaleyArizona Cancer Evolution Center, Arizona State University, Tempe, Arizona.ORCID 0000-0002-0745-7076

Funding

PHYLOGENIES of Barrett's Esophagus LineagesP01CA091955 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY · 2002 to 2019
$35.9M
Molecular, Cellular and Tissue Characterization UnitU2CCA233254 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY · 2018 to 2023
$11.4M
The Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6M
Modeling Neoplastic Progression in Barrett's Esophagus - Renewal -2R01CA140657 · NCI · WISTAR INSTITUTE · PI Carlo Maley · 2009 to 2026
$5.0M
T32 Cancer Prevention and Control Training Program Addressing Health DisparitiesT32CA272303 · NCI · UNIVERSITY OF ARIZONA · PI Terry A Badger, Gloria D. Coronado · 2023 to 2026
$1.1M
A cell-cycle induced genetic recorder for simultaneous recovery of cell divisions and lineageR21CA257980 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MALEY, CARLO, WEISS, RON · 2022 to 2023
$576k
Arizona Biomedical Research Commission (ABRC) ADHS18-198847Congressionally Directed Medical Research Programs (CDMRP) BC132057National Cancer Institute (NCI) P01 CA91955National Institute of Food and Agriculture (NIFA) 2021-70006-35385NCI NIH HHS P01 CA091955NCI NIH HHS R01 CA140657NCI NIH HHS R21 CA257980NCI NIH HHS T32 CA272303NCI NIH HHS U2C CA233254NCI NIH HHS U54 CA217376
6 · The paper itself

Abstract

One of the main reasons we have not been able to cure cancers is that treatments select for drug-resistant cells. Pest managers face similar challenges with pesticides selecting for pesticide-resistant insects, resulting in similar mechanisms of resistance. Pest managers have developed 10 principles that could be translated to controlling cancers: (i) prevent onset, (ii) monitor continuously, (iii) identify thresholds below which there will be no intervention, (iv) change interventions in response to burden, (v) preferentially select nonchemical control methods, (vi) use target-specific drugs, (vii) use the lowest effective dose, (viii) reduce cross-resistance, (ix) evaluate success based on long-term management, and (x) forecast growth and response. These principles are general to all cancers and cancer drugs and so could be employed broadly to improve oncology. Here, we review the parallel difficulties in controlling drug resistance in pests and cancer cells. We show how the principles of resistance management in pests might be applied to cancer. Integrated pest management inspired the development of adaptive therapy in oncology to increase progression-free survival and quality of life in patients with cancers where cures are unlikely. These pest management principles have the potential to inform clinical trial design.

Indexed as

Drug Resistance, NeoplasmNeoplasmsAnimalsAntineoplastic AgentsFarmersHumansAntineoplastic Agents

Identifiers

PMID39356625
PMCPMC11565176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.